Salud financiera de hoja de balance de Arbutus Biopharma
Salud financiera controles de criterios 5/6
Arbutus Biopharma tiene un patrimonio de los accionistas total de $106.0M y una deuda total de $7.0M, lo que sitúa su ratio deuda-patrimonio en 6.6%. Sus activos y pasivos totales son $144.4M y $38.4M respectivamente.
Información clave
6.6%
Ratio deuda-patrimonio
US$6.95m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$126.00m |
| Patrimonio | US$106.02m |
| Total pasivo | US$38.38m |
| Activos totales | US$144.40m |
Actualizaciones recientes sobre salud financiera
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10
We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Recent updates
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
May 21Arbutus Bio slips 4% as Q1 revenue trails consensus
May 05What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition
Mar 12We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Feb 02Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years
Jan 07Arbutus Biopharma (ABUS) Investor Presentation - Slideshow
Dec 17Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($132.0M) de ABUS superan a sus pasivos a corto plazo ($22.5M).
Pasivo a largo plazo: Los activos a corto plazo de ABUS ($132.0M) superan a sus pasivos a largo plazo ($15.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ABUS tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de ABUS ha crecido de 0% a 6.6% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ABUS tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ABUS dispone de suficiente cash runway para 1.3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 1% cada año.